The Monsters She Faced and the Woman She Found: Author Angie Lickliter Shares Her Journey of Healing and Hope in ‘Finding Her'
KANSAS CITY, MO / ACCESS Newswire What if the greatest love story you'll ever live is the one you write with yourself? In a world full of expectations, author Angie Lickliter invites women to pause, reflect upon themselves, and bravely confront the monsters that have held them back. Finding Her isn't just a memoir, but a moving life story for women ready to face their pain, rewrite their story, and step into the life they were meant to live.
In her debut memoir, Finding Her, Angie Lickliter shares the raw, unfiltered story of her journey through chronic illness, self-doubt, and healing. Diagnosed with Crohn's disease at the age of 27, she has spent decades navigating a battlefield of physical pain, emotional isolation, and inner chaos. Her story is not one of overnight transformation, but of deep work, relentless self-discovery, and finally, self-acceptance.
'I didn't just write Finding Her, I lived it,' says Lickliter. 'Page by page, I faced the monsters that once defined me: shame, heartbreak, the battle with my body, and the silence of not feeling enough. This book is my victory. It's a message to every woman that healing is possible. You can rise. You can rewrite your story. And you can find her, because she's still in there.'
Published on June 2 by Landon Hail Press, Finding Her quickly rose to become the #6 New Release in Women's Personal Growth and a Top New Release in Women's Spiritual Growth. It also ranked #2 in New Releases for Family & Personal Growth. Book cover design by Rich Johnson of Spectacle Photography, with photography by Angelli Nguyen and creative direction by Samantha Joy.
Finding Her is more than a memoir; it's a roadmap for anyone who has ever felt broken, invisible, or unsure of where to turn next. Through raw storytelling and deep honesty, Angie offers her readers a gripping account of her personal battles with the inner 'monsters' that once threatened to define her.
Designed to lead readers through Angie's journey from start to finish, Finding Her gives readers a firsthand account of the encounters with her monsters, who all represent a fear or shame Angie felt at one point in time. Along the way, the readers also meet the author's 'allies', who are unexpected people, practices, and moments of clarity that helped her survive. The book concludes with an empowering collection of 'weapons' – or tools – like meditation, yoga, journaling, and more, that helped Angie become stronger and more self-aware after every battle.
This book was written to empower you, the reader, to face your own monsters with courage and clarity. While everyone's monsters are different, they all whisper doubts, reinforce patterns, and keep you stuck in shadows. Angie's story, with the tools that she provides, proves that with the right support and inner work, healing isn't just possible, it's inevitable.
'Angie's bravery to shed the monsters that once shaped her identity is the permission every woman needs to overcome a false sense of self,' says Samantha Joy, Editor-in-Chief at Landon Hail Press. ' Finding Her encourages you to embark on the journey back to who you were before the world told you who to be.'
Author Angie Lickliter shines beautifully as she is photographed by Angelli Nguyen. Creative direction by Samantha Joy.
For over 25 years, Angie has lived with Crohn's disease, which has greatly influenced her own personal battles with food, alcohol, and toxic relationships. Angie brings both vulnerability and wisdom to the pages of her memoir. Her work as a certified holistic wellness and cannabis coach, along with her leadership of countless support groups, fuels her mission to empower women to reclaim their health, identity, and power.
This summer, Finding Her dares women to slow down, look inward, and ask the bigger questions in order to discover their true selves.
'I wrote Finding Her to tell my story,' Angie says. 'I built Finding Her to help you rewrite yours.'
Dedicated to creating a sacred and transparent space for writers, Landon Hail Press allows authors to own the creative direction of their book and their brand. LHP books have been sold on Amazon, Barnes & Noble, bookshop.org, and more, and featured in major publications like People.com.
Are you an aspiring author? Book a free consultation with Landon Hail Press here.
For further information, please contact: dottie@rebeccacafiero.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 hours ago
- Yahoo
How Will Quantum Technologies Transform the $9.8 Trillion Global Healthcare Sector?
A recent publication by quantum researcher Ali Karakuş draws the attention of the medical industry. BERLIN, DE / / June 5, 2025 / Quantum researcher Ali Karakuş has published a groundbreaking scientific paper that challenges the foundations of modern medicine and proposes a bold new perspective on health. The study introduces a next-generation medical model based on quantum sensors, ethical artificial intelligence, and resonance-based diagnostics-aiming to redefine our understanding of illness and healing. Global healthcare expenditures now exceed $9.8 trillion per year. Yet, despite this enormous financial investment, chronic illnesses, mental health disorders, and stress-related conditions are on the rise. According to Karakuş, the problem is not technological scarcity but the loss of harmonic alignment between humans, nature, and their own bodies. "We measure numbers but fail to listen to frequencies," says Karakuş. "We treat symptoms, yet overlook resonance breakdowns. The body must no longer be viewed as matter alone, but as a field of waves and energy." From Symptom Suppression to Resonance Restoration At the heart of the study is a quantum-sensor-based device in development that analyzes brainwaves, heart rate variability (HRV), vagus nerve activity, microbiome signals, and ethical resonance scores. All of this data is then processed by an ethical AI engine called Zulficore, producing a holistic and personalized feedback loop. A New Question for Medicine: "What's wrong?" or "What's out of tune?" The system designed by SlientWing integrates multiple disciplines including quantum biology, neuroscience, biomimetics, ecological AI, and ethics-based algorithms. The core question is shifting: Not "What disease do you have?" But "What frequency is disturbed? Which resonance with nature is lost?" Launch Timeline The beta version of the SlientWing device is expected to be field-tested by late 2026, with full-scale production and market launch scheduled for 2027. Manufacturing will be centered in Berlin and Thrace. Contact Information Ali Karakus Founderali@ SOURCE: Neuroscience & Quantum Researcher Ali Karakus View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Indianapolis Star
14 hours ago
- Indianapolis Star
New to The Street Signs National Media Agreement with NRx Pharmaceuticals for 12-Part Broadcast Series Across TV, Digital, and Outdoor Platforms
NEW YORK CITY, NEW YORK / ACCESS Newswire New to The Street, the nation's leading multi-platform financial news show, today announced it has signed a 12-part media partnership with NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), a clinical-stage biopharmaceutical company focused on life-saving therapies for patients with suicidal depression, PTSD, and chronic pain. The partnership will feature monthly televised interviews with NRx CEO Dr. Jonathan Javitt, providing updates from the front lines of biotech innovation. As part of the comprehensive campaign, New to The Street will also produce earned media placements on ABC, NBC, and CBS affiliates, a full suite of nationally aired TV commercials, and premium outdoor billboard exposure in Times Square and throughout the NYC Financial District. 'Our mission has always been to save lives with science,' said Jonathan Javitt, MD, MPH, Founder and CEO of NRx Pharmaceuticals. 'Partnering with New to The Street enables us to share the life-saving potential of NRX-101 and our broader pipeline with a national audience, at a pivotal moment in our regulatory and commercial path.' 'We are proud to bring NRX's critical work to our global audience,' said Vince Caruso, Co-Founder and CEO of New to The Street. 'This series will spotlight a company on the front lines of neuroscience and public health, and exemplifies our commitment to covering stories that matter-with scale, credibility, and impact.' The series begins airing later this month on Fox Business and Bloomberg Television as sponsored programming, reaching more than 245 million homes weekly across the U.S. and Middle East. Episodes will also stream on New to The Street's YouTube channel, which now exceeds 2.5 million subscribers, and be supported by billboard takeovers in Times Square and full media amplification through the NewsOut™ and platforms. About NRx Pharmaceuticals, Inc. NRx Pharmaceuticals (NASDAQ: NRXP) is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for treating central nervous system disorders. Its lead investigational drug, NRX-101, has been granted FDA Breakthrough Therapy and Fast Track Designation for suicidal bipolar depression. The company is also pursuing accelerated approval for preservative-free IV ketamine (NRX-100) and advancing additional treatments for PTSD, chronic pain, and UTIs. Learn more at About New to The Street New to The Street is a leading branded content TV series that features innovative public and private companies on national television, including Fox Business and Bloomberg Television. With more than 2.52 million YouTube subscribers, a reach of 245 million TV households, and a powerful outdoor media footprint, the platform offers unmatched exposure across digital, television, and out-of-home channels. Learn more at SOURCE: New To The Street View the original press release on ACCESS Newswire
Miami Herald
21 hours ago
- Miami Herald
Telomir Pharmaceuticals Announces Telomir-1 Resets the Body's Epigenetic Clock, Reverses DNA Methylation, and Restores Youthful Gene Regulation in an Ultra-Rare Accelerated Aging Animal Model of Werner Syndrome
Treatment restored gene control, extended telomere length beyond healthy levels, reversed muscle and weight loss, reduced oxidative stress, and resulted in 100% survival - highlighting Telomir-1's potential to reverse key hallmarks of aging MIAMI, FL / ACCESS Newswire / June 5, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), or the "Company," an emerging leader in age-reversal science, today announced compelling new preclinical data demonstrating that its lead candidate, Telomir-1, administered orally, significantly increases telomere length, reverses body weight and muscle loss, and resets cellular aging markers in a validated animal model of Werner Syndrome (WS)-a rare genetic disorder also known as adult-onset progeria. These findings confirm and build upon the Company's previously reported results from a preclinical C. elegans study, which demonstrated that Telomir-1 restored lifespan and normalized physiological decline in animals with a wrn gene mutation. Werner Syndrome: A Rare and Devastating Accelerated Aging Disorder Werner Syndrome is a rare autosomal recessive disorder caused by mutations in the wrn gene, which plays a critical role in DNA repair and telomere maintenance. Patients typically begin showing signs of premature aging-such as graying hair, cataracts, diabetes, osteoporosis, and atherosclerosis-in their 20s or 30s. Median life expectancy is 40-50 years. There are currently no FDA-approved treatments. To model this disease, the Company's study utilized the Sen57wrn-/-ND6-/+ zebrafish model, which replicates key features of Werner Syndrome, including telomere loss, mitochondrial dysfunction, retinal degeneration, muscle deterioration, and abnormal DNA methylation. Key Preclinical Findings 1. DNA Methylation Reversal - Resetting the Genetic ClockDNA methylation is one of the body's key mechanisms for controlling which genes are turned on or off. It works by attaching small chemical tags (called methyl groups) to DNA at locations known as CpG islands-which act like gene "on/off" switches. When methylation patterns are intact, cells know which genes to express and when. However, with aging and disease, this regulatory system starts to break down - a phenomenon known as epigenetic drift. In these cases, genes that should be off may turn on inappropriately, and protective genes may be silenced. This malfunction in gene regulation is strongly linked to a wide range of chronic diseases including: Cancer (via silencing of tumor suppressor genes)Neurodegenerative diseases like Alzheimer's and Parkinson'sAutoimmune diseases such as lupus and multiple sclerosisMetabolic conditions like Type 2 diabetesPremature aging disorders like progeria and Werner Syndrome In this study, Telomir-1 reversed age-related hypomethylation at two chromosomal regions, restoring methylation patterns to above-normal wild-type levels. This suggests that Telomir-1 may help restore healthy gene regulation and reset the body's epigenetic aging clock, reducing the risk of dysfunction in key biological systems. 2. Telomere Elongation - Rebuilding the Chromosomal ClockTelomeres are the protective caps at the ends of chromosomes that shorten with each cell division and under stress. Telomere shortening is considered one of the hallmarks of aging. In the study, compared with the shortened length in the mutated animals, Telomir-1 increased telomere length by about three-fold. At the higher dose, telomere length significantly exceeded wild-type (healthy) levels, suggesting not only restoration but also potential enhancement of chromosomal integrity 3. Muscle Mass and Body Weight RecoveryIn the wrn-mutant zebrafish model, animals exhibited a 50-60% reduction in body weight and muscle volume. After 14 days of Telomir-1 treatment, these physical markers were restored to levels statistically indistinguishable from healthy controls - indicating functional recovery and metabolic improvement. 4. Oxidative Stress ReductionReactive oxygen species (ROS), which damage cells and accelerate aging, were elevated in untreated animals. Telomir-1 reduced ROS levels by up to 50%, suggesting improved cellular resilience. 5. Survival BenefitRoughly 15% of untreated animals died during the 14-day study period, whereas no deaths occurred in any Telomir-1 treated groups - highlighting a systemic survival advantage. "These results reinforce my conviction that Telomir-1 may represent one of the most important scientific developments in the field of aging," said Erez Aminov, Chairman and CEO of Telomir. "While we remain in the preclinical phase, the consistency and strength of the data demand serious attention. My full commitment is behind advancing Telomir-1 toward human studies in the most responsible and rigorous way. The potential here is too significant to ignore." "This is one of the most comprehensive rejuvenation profiles we've seen in a vertebrate aging model," added Dr. Itzchak Angel, Chief Scientific Advisor. "The ability to reverse both genomic and epigenetic instability while improving survival supports the growing potential of Telomir-1 as a foundational therapy for aging-related diseases." Cautionary Note Regarding Forward-Looking Statements This press release, statements of Telomir's management or advisors related thereto, and the statements contained in the news story linked in this release contain "forward-looking statements," which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These risks and uncertainties include, but are not limited to, the potential use of the data from our studies, our ability to develop and commercialize Telomir-1 for specific indications, and the safety of Telomir-1. Any forward-looking statements in this press release are based on Telomir's current expectations, estimates and projections only as of the date of this release. These risks and uncertainties include, but are not limited to, the potential use of the data from our studies, our ability to develop and commercialize Telomir-1 for specific indications and safety of Telomir-1. These and other risks concerning Telomir's programs and operations are described in additional detail in its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which is on file with the SEC. Telomir explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law. Contact Information Helga Moya info@ 396-6723 SOURCE: Telomir Pharmaceuticals, Inc
